Systemic sclerosis (SSc) is a chronic autoimmune connective tissue disease that affects the skin, internal organs, and musculoskeletal system. It is common for Raynaud’s phenomenon (RP) to be the first manifestation of SSc and it is present in most patients. Frequent vasoconstriction along with structural changes in the capillaries, make these patients more susceptible to developing digital ulcers and pain in the peripheral joints. The aim of this study was to evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) as a therapeutic option for patients with SSc and RP. The study was conducted at the Clinical Hospital "Sveti Duh" and the "Oxy" Polyclinic for hyperbaric and occupational medicine in Zagreb. The study included 29 participants, 3 men (10%) and 26 women (90%) with an average age of 56±11 years. Most participants had an unspecified form of SSc, 18 (62%), while 7 (24%) had a limited form, and 4 (14%) had a diffuse form of the disease. As a measure of therapy effectiveness, the visual analogue scale (VAS) was used to assess pain in peripheral joints and general fatigue before and after completed therapy in the hyperbaric chamber. The obtained values were compared, and there was a statistically significant difference in VAS values before and after HBOT was completed, with a p-value <0.05. Additionally, each participant was given the SF-36 quality of life questionnaire, which showed a reduced quality of life in all categories. The results showed a significant reduction in peripheral joint pain and general fatigue after HBOT, indicating the potential benefit of this therapy in improving the quality of life for those affected. No significant difference was observed in the effectiveness and response to HBOT between younger and older patients. However, due to the limited number of participants, further research is needed to confirm these results.